REGN vs T · P/E 14, rev $14.34B vs P/E 7.4, rev $125.65B
Regeneron Pharmaceuticals Inc (REGN) versus AT&T Inc. (T) — a side-by-side from cached financials, not a winner call.
Regeneron Pharmaceuticals Inc (REGN) is a biotechnology company listed on US.
AT&T Inc. (T) is a telecom services company listed on NYSE. It is led by John Stankey.
Latest reported REGN revenue for 2025-12-31 was $14.34B. Net income was $4.50B. Revenue was up 1.0% from 2024-12-31 to 2025-12-31. REGN currently screens at market cap $59.10B and trailing P/E 13.9.
Latest reported T revenue for 2025-12-31 was $125.65B. Net income was $21.95B. Revenue was up 2.7% from 2024-12-31 to 2025-12-31. T currently screens at market cap $155.92B and trailing P/E 7.4.
REGN currently screens at market cap $59.10B and trailing P/E 13.9. T currently screens at market cap $155.92B and trailing P/E 7.4.
Not investment advice. Open the REGN and T stock pages for the full models.
Not investment advice.